Detalhe da pesquisa
1.
Efficacy and safety of the oral Janus kinase 1 inhibitor povorcitinib (INCB054707) in patients with hidradenitis suppurativa in a phase 2, randomized, double-blind, dose-ranging, placebo-controlled study.
J Am Acad Dermatol
; 90(3): 521-529, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-37871805
2.
Validation of the Physician's Global Assessment of Fingernail Psoriasis by Rheumatologists Treating Psoriatic Arthritis.
Value Health
; 25(9): 1582-1589, 2022 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-35623975
3.
Hidradenitis Suppurativa: Diagnosis and Management in the Emergency Department.
J Emerg Med
; 63(5): 636-644, 2022 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-36243614
4.
What causes hidradenitis suppurativa ?-15 years after.
Exp Dermatol
; 29(12): 1154-1170, 2020 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-33058306
5.
Two Phase 3 Trials of Adalimumab for Hidradenitis Suppurativa.
N Engl J Med
; 375(5): 422-34, 2016 Aug 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-27518661
6.
Long-term adalimumab efficacy in patients with moderate-to-severe hidradenitis suppurativa/acne inversa: 3-year results of a phase 3 open-label extension study.
J Am Acad Dermatol
; 80(1): 60-69.e2, 2019 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-29860040
7.
The promise of personalized medicine for hidradenitis suppurativa.
Br J Dermatol
; 188(1): 3, 2023 01 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-36689524
8.
Adalimumab for nail psoriasis: Efficacy and safety from the first 26 weeks of a phase 3, randomized, placebo-controlled trial.
J Am Acad Dermatol
; 78(1): 90-99.e1, 2018 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-28993005
9.
Achieving Hidradenitis Suppurativa Response Score is Associated with Significant Improvement in Clinical and Patient-reported Outcomes: Post Hoc Analysis of Pooled Data From PIONEER I and II.
Acta Derm Venereol
; 98(10): 932-937, 2018 Nov 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-30085324
10.
Poor early response to methotrexate portends inadequate long-term outcomes in patients with moderate-to-severe psoriasis: Evidence from 2 phase 3 clinical trials.
J Am Acad Dermatol
; 77(6): 1030-1037, 2017 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-28993007
11.
Uncovering burden disparity: A comparative analysis of the impact of moderate-to-severe psoriasis and hidradenitis suppurativa.
J Am Acad Dermatol
; 77(6): 1038-1046, 2017 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-28917381
12.
Patients' willingness to accept adverse event and cost tradeoffs from oral nicotinamide for reduced risk of non-melanoma skin cancer.
J Dermatolog Treat
; 34(1): 2247105, 2023 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-37587862
13.
Outcome Measures for the Evaluation of Treatment Response in Hidradenitis Suppurativa for Clinical Practice: A HiSTORIC Consensus Statement.
JAMA Dermatol
; 159(11): 1258-1266, 2023 11 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37755725
14.
Switching to adalimumab for psoriasis patients with a suboptimal response to etanercept, methotrexate, or phototherapy: efficacy and safety results from an open-label study.
J Am Acad Dermatol
; 64(4): 671-81, 2011 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-21414495
15.
Clinical Epidemiology and Management of Hidradenitis Suppurativa.
Obstet Gynecol
; 137(4): 731-746, 2021 04 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33706337
16.
Adalimumab treatment is associated with improvement in health-related quality of life in psoriasis: patient-reported outcomes from a phase II randomized controlled trial.
J Dermatolog Treat
; 18(1): 25-31, 2007.
Artigo
em Inglês
| MEDLINE | ID: mdl-17365264
17.
Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study.
J Am Acad Dermatol
; 55(4): 598-606, 2006 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-17010738
18.
The validity and responsiveness of three quality of life measures in the assessment of psoriasis patients: results of a phase II study.
Health Qual Life Outcomes
; 4: 71, 2006 Sep 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-17005043
19.
Adalimumab treatment optimization for psoriasis: Results of a long-term phase 2/3 Japanese study.
J Dermatol
; 42(11): 1042-52, 2015 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-26118825
20.
Psoriasis Area and Severity Index: nuts and bolts of measuring disease severity in psoriasis.
Clin Dermatol
; 26(6): 653-6, 2008.
Artigo
em Inglês
| MEDLINE | ID: mdl-18940548